Balyasny Asset Management
VNDA icon

Balyasny Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Balyasny Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$397K Sell
64,927
-40,162
-38% -$262K ﹤0.01% 2616
2026
Q1 		$726K Buy
105,089
+36,911
+54% +$285K ﹤0.01% 2210
2025
Q4 		$601K Buy
+68,178
New +$375K ﹤0.01% 2439
2025
Q2 		– Sell
-24,694
Closed -$113K – 3397
2025
Q1 		$113K Buy
+24,694
New +$115K ﹤0.01% 2672
2023
Q4 		– Sell
-157,153
Closed -$679K – 2943
2023
Q3 		$679K Buy
157,153
+146,864
+1,427% +$816K ﹤0.01% 1664
2023
Q2 		$67.8K Buy
+10,289
New +$66K ﹤0.01% 2129
2023
Q1 		– Sell
-40,088
Closed -$296K – 3192
2022
Q4 		$296K Buy
40,088
+29,970
+296% +$292K ﹤0.01% 1999
2022
Q3 		$100K Buy
+10,118
New +$107K ﹤0.01% 2407
2019
Q3 		– Sell
-20,197
Closed -$285K – 1620
2019
Q2 		$285K Buy
+20,197
New +$321K ﹤0.01% 1329
2018
Q2 		– Sell
-24,617
Closed -$415K – 2174
2018
Q1 		$415K Buy
24,617
+14,117
+134% +$236K ﹤0.01% 1505
2017
Q4 		$160K Sell
10,500
-11,400
-52% -$169K ﹤0.01% 1937
2017
Q3 		$392K Buy
+21,900
New +$366K ﹤0.01% 1429
2016
Q2 		– Sell
-25,600
Closed -$214K – 1470
2016
Q1 		$214K Sell
25,600
-12,860
-33% -$106K ﹤0.01% 1111
2015
Q4 		$358K Buy
38,460
+5,260
+16% +$52.5K ﹤0.01% 920
2015
Q3 		$374K Buy
33,200
+22,100
+199% +$270K ﹤0.01% 868
2015
Q2 		$141K Buy
+11,100
New +$120K ﹤0.01% 1051
2014
Q2 		– Sell
-225,480
Closed -$3.66M – 782
2014
Q1 		$3.66M Buy
+225,480
New +$3.21M 0.04% 412
2013
Q3 		– Sell
-105,000
Closed -$848K – 726
2013
Q2 		$848K Buy
+105,000
New +$707K 0.01% 502

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's VNDA Position: Q2 2026 in Review

Balyasny Asset Management reduced its Vanda Pharmaceuticals (VNDA) stake by 38% in Q2 2026, selling an estimated $262K and leaving 64,927 shares worth $397K. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

Balyasny Asset Management first reported a position in VNDA in Q2 2013 and has held it in 18 quarters since. The position peaked at $3.66M in Q1 2014. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Balyasny Asset Management held 64,927 shares of Vanda Pharmaceuticals worth $397K as of Q2 2026.
  • Balyasny Asset Management sold 40,162 Vanda Pharmaceuticals shares in Q2 2026, an estimated $262K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2616 holding.
  • Balyasny Asset Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
  • Balyasny Asset Management's Vanda Pharmaceuticals position peaked at $3.66M in Q1 2014.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.